[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:renal-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":313,"states":336},"Renal Cell Carcinoma",147,127,[8,16,23,30,36,42,48,54,60,66,72,78,85,91,97,103,109,115,121,127,133,139,144,150,156,162,168,174,180,186,192,198,204,210,216,222,229,235,241,247,253,259,265,271,277,283,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06794229","Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and\u002For Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis",[12],"Phase 2","RECRUITING","2026-08-26T02:16:20.336282Z","2026-07-05T05:32:16.697605Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07227415","Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:56.409949Z","2026-07-05T05:32:16.667968Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05700461","Drug Screening Using Novel IMD in Renal Cell Carcinoma",[27],"Phase 1","2026-08-26T02:18:32.765187Z","2026-05-29T15:36:40.166256Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07128680","Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer",[27],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.710447Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06376669","Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma",[12],"2026-08-26T02:19:17.380174Z","2026-05-05T02:43:29.691711Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07179770","Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)",[27],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.659155Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05048212","A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",[12],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:29.384523Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06005818","Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)",[12],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:29.372544Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06222593","Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC",[20],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:29.337795Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05155033","Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma",[12],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:29.184021Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07397611","Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC",[12],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:29.134880Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":83,"content_modified":84},"NCT07092566","R.E.C.K vs Exparel in Robotic Nephrectomy",[82],"Phase 3","2026-08-26T02:18:06.247899Z","2026-05-05T02:43:29.077161Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05969496","Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus",[12],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:29.040656Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07049926","Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C\u002FKEYMAKER-U03)",[20],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:28.985509Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07188896","A Randomized Trial of Fianlimab and Cemiplimab +\u002F- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)",[12],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:28.563453Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06708949","A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)",[12],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.484871Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT04974671","Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma",[12],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:28.482687Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06399419","CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer",[27],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:28.290171Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT03592472","A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)",[82],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:28.212072Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT01890590","A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma",[],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:28.184695Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT07293351","A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)",[20],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.947314Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":95,"content_modified":143},"NCT07011719","Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma",[82],"2026-05-05T02:43:27.832119Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT05263050","Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors",[12],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.800671Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06866262","Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial",[20],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:27.747263Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT04510597","Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",[82],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.333582Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT05319015","Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus",[12],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:27.286722Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT06004336","A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)",[12],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:27.128269Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT06432036","Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial",[20],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:26.907678Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT06699602","A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma",[12],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:26.747869Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT03972657","A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors",[20],"2026-08-26T02:19:11.399072Z","2026-05-05T02:43:26.693701Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT07401875","A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)",[27],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:26.693693Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT07037004","Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery",[12],"2026-08-26T02:15:01.639696Z","2026-05-05T02:35:31.931574Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT05327686","Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",[12],"2026-08-26T02:18:39.640967Z","2026-05-05T02:35:31.931526Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT07219576","Retifanlimab and Ruxolitinib In Solid Malignancies",[20],"2026-08-26T02:15:14.574786Z","2026-05-05T02:35:31.871524Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[12],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":227,"content_modified":228},"NCT05733715","Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma",[226],"Early Phase 1","2026-08-26T02:15:02.712396Z","2026-05-05T02:35:31.751306Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT05931393","Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)",[12],"2026-08-26T02:16:35.654046Z","2026-05-05T02:35:31.672320Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT04473781","Interstitial Brachytherapy for the Treatment of Unresectable\u002FUnablatable Kidney Cancer",[27],"2026-08-03T01:56:45.025842Z","2026-05-05T02:35:31.653834Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT06863311","Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC",[12],"2026-08-26T02:18:14.396999Z","2026-04-29T02:57:57.078355Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT07419841","A Phase 1 Study of the Safety and Tolerability of CTX-10726",[27],"2026-08-26T02:18:55.570428Z","2026-07-05T05:32:16.684256Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT07160335","A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors",[27],"2026-08-03T01:00:27.952609Z","2026-07-05T05:32:16.658020Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT05363280","Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment",[12],"2026-08-26T02:17:38.215063Z","2026-05-13T02:55:06.301970Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT05830058","Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma",[12],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:29.184830Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT06413680","A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body",[20],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:29.042307Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT04981509","Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.854522Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT06259552","A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors",[27],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:28.361411Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT07405164","Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043\u002FLITESPARK-043)",[82],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.259860Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT06966024","Study of DCC-2812 in Participants With Advanced Genitourinary Cancers",[27],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:26.722480Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT06101290","Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)",[],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.729627Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":311,"content_modified":312},"NCT06792552","A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:16:13.426928Z","2026-07-30T01:46:14.431650Z",[314,318,322,326,329,333],{"biomarker":315,"count":316,"slug":317},"MSI1 Gene",11,"msi1-gene",{"biomarker":319,"count":320,"slug":321},"MRC1 wt Allele",7,"mrc1-wt-allele",{"biomarker":323,"count":324,"slug":325},"Programmed Cell Death 1 Ligand 1",5,"programmed-cell-death-1-ligand-1",{"biomarker":327,"count":324,"slug":328},"TPM2 wt Allele","tpm2-wt-allele",{"biomarker":330,"count":331,"slug":332},"Programmed Cell Death Protein 1",3,"programmed-cell-death-protein-1",{"biomarker":334,"count":331,"slug":335},"Soluble Epidermal Growth Factor Receptor","soluble-epidermal-growth-factor-receptor",[337,341,345,349,353,357,361,365,368,372,376,380,384,387,391,395,398,402,405,409,412,416,420,423],{"state":338,"count":339,"slug":340},"Texas",65,"texas",{"state":342,"count":343,"slug":344},"California",54,"california",{"state":346,"count":347,"slug":348},"New York",41,"new-york",{"state":350,"count":351,"slug":352},"Florida",36,"florida",{"state":354,"count":355,"slug":356},"Pennsylvania",33,"pennsylvania",{"state":358,"count":359,"slug":360},"Michigan",28,"michigan",{"state":362,"count":363,"slug":364},"Ohio",27,"ohio",{"state":366,"count":363,"slug":367},"Tennessee","tennessee",{"state":369,"count":370,"slug":371},"Massachusetts",23,"massachusetts",{"state":373,"count":374,"slug":375},"Arizona",22,"arizona",{"state":377,"count":378,"slug":379},"New Jersey",20,"new-jersey",{"state":381,"count":382,"slug":383},"Minnesota",19,"minnesota",{"state":385,"count":382,"slug":386},"Missouri","missouri",{"state":388,"count":389,"slug":390},"Maryland",18,"maryland",{"state":392,"count":393,"slug":394},"Illinois",17,"illinois",{"state":396,"count":393,"slug":397},"North Carolina","north-carolina",{"state":399,"count":400,"slug":401},"Georgia",16,"georgia",{"state":403,"count":400,"slug":404},"Washington","washington",{"state":406,"count":407,"slug":408},"Colorado",15,"colorado",{"state":410,"count":407,"slug":411},"Virginia","virginia",{"state":413,"count":414,"slug":415},"Connecticut",14,"connecticut",{"state":417,"count":418,"slug":419},"Oregon",12,"oregon",{"state":421,"count":316,"slug":422},"Nebraska","nebraska",{"state":424,"count":316,"slug":425},"Wisconsin","wisconsin"]